Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments

Transfusion and Apheresis Science

Volumn 39, Issue 2, 2008, Pages 115-121

  Cid, Joan ^a   Ramiro, Laia ^a   Martínez, Nuria ^a   Palomo, Marta ^b   Magallon, Olga ^a   Claparols, Montse ^a   Ortiz, Pilar ^a   Puig, Lluis ^a   Pla, Ramon Pau ^a  

^a BANC DE SANG I TEIXITS   (Spain)

^b Hospital Clinic   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; BLOOD CLOTTING FACTOR; FRESH FROZEN PLASMA; METHYLENE BLUE;

ARTICLE; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; BLOOD LEVEL; BLOOD VOLUME; HUMAN; LIGHT; NORMAL HUMAN; PHOTOCHEMISTRY; PROTEIN ANALYSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; ULTRAVIOLET A RADIATION;

BLOOD COAGULATION FACTORS; BLOOD PROTEINS; BLOOD-BORNE PATHOGENS; FIBRINOGEN; HUMANS; LIGHT; METHYLENE BLUE; PHOTOCHEMISTRY; PLASMA; PSORALENS; ULTRAVIOLET RAYS; VIRUS INACTIVATION; VON WILLEBRAND FACTOR;

EID: 53249130666     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2008.07.009     Document Type: Article

References (29)

1. Corash L. Virus-safe products: pathogen reduction and inactivation. In: Hillyer C.D., Silberstein L.E., Ness P.M., Anderson K.C., and Roback J.D. (Eds). Blood banking and transfusion medicine (2007), Elsevier, Philadelphia p. 383-96
2. Wendel S., and Barbara J.A.J. Infectious disease testing. In: Lozano M., Contreras M., and Blajchman M. (Eds). Global perspectives in transfusion medicine (2006), AABB Press, Bethesda p. 55-101
3. Solheim B.G., Cid J., and Osselaer J.C. Pathogen reduction technologies. In: Lozano M., Contreras M., and Blajchman M. (Eds). Global perspectives in transfusion medicine (2006), AABB Press, Bethesda p. 103-48
4. Bopp M.K.F., Morell A., Indrak K., Parkkinen J., Mertens H., Mohr H., et al. Pathogen inactivation of labile blood products. Transfus Med 11 (2001) 149-175
5. Lambrecht B., Mohr H., Knuver-Hopf J., and Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60 (1991) 207-213
6. Cid J., Claparols M., Pinacho A., Hernandez J.M., Ortiz P., Puig L.S., et al. Comparison of blood component preparation methods from whole blood bags based on buffy coat extraction. Transfus Apher Sci 36 (2007) 243-247
7. Guide to the preparation, use and quality assurance of blood components, 11th edn. Strasburg, Council of Europe Publishing, 2005.
8. Kokame K., Nobe Y., Kokubo Y., Okayama A., and Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129 (2005) 93-100
9. Williamson L.M., Cardigan R., and Prowse C.V. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion 43 (2003) 1322-1329
10. Zeiler T., Riess H., Wittmann G., Hintz G., Zimmermann R., Muller C., et al. The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single- donor fresh-frozen plasma. Transfusion 34 (1994) 685-689
11. Depasse F., Sensebe L., Seghatchian J., Andreu G., and Samama M.M. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. Transfus Apher Sci 33 (2005) 63-69
12. Atance R., Pereira A., and Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41 (2001) 1548-1552
13. Pereira A. Methylene-blue-photoinactivated plasma and its contribution to blood safety. Transfusion 44 (2004) 948-950
14. Cid J., Puig L., Pla R.P., and Hernandez J.M. (Over) use of methylene blue-treated fresh frozen plasma?. 7-years experience. Transfusion 45(Suppl) (2005) 74A
15. Hornsey V.S., Drummond O., Young D., Docherty A., and Prowse C.V. A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfusion Med 11 (2001) 31-36
16. Hornsey V., Young D., and Prowse C. Cryoprecipitate prepared from methylene blue-treated fresh plasma. Transfusion 41 (2001) 151-152
17. Hornsey V.S., Krailadsiri P., MacDonald S., Seghatchian J., Williamson L.M., and Prowse C.V. Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma. Br J Haematol 109 (2000) 665-670
18. Aznar J.A., Montoro J.M., Cid A.R., Bonanad S., Hurtado C., Soler M.A., et al. Clotting factors in cryoprecipitate and cryosupernatant prepared from MB-treated fresh plasma. Transfusion 40 (2000) 493
19. Aznar J.A., Molina R., and Montoro J.M. Factor VIII von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 39 (1999) 748-750
20. Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., and Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14 (2004) 39-44
21. Cardigan R., Allford S., and Williamson L. Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. Br J Haematol 117 (2002) 253-254
22. Garwood M., Cardigan R.A., Drummond O., Hornsey V.S., Turner C.P., Young D., et al. The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 43 (2003) 1238-1247
23. de la Rubia J., Arriaga F., Linares D., Larrea L., Carpio N., Marty M.L., et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Brit J Haematol 114 (2001) 721-723
24. Alvarez-Larran A., Del Rio J., Ramirez C., Albo C., Pena F., Campos A., et al. Methylene blue-photoinactivated plasma vs Fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 86 (2004) 246-251
25. Muncunill J., Del Rio J., and A A.-L. Methylen blue photoinactivated plasma vs FFP in TTP treatment: a multicentric prospective cohort study. Transfusion 47(Suppl) (2007) 14A
26. Singh Y., Sawyer L.S., Pinkoski L.S., Dupuis K.W., Hsu J.C., Lin L., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46 (2006) 1168-1177
27. Mintz P.D., Neff A., MacKenzie M., Goodnough L.T., Hillyer C., Kessler C., et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 46 (2006) 1693-1704
28. Osselaer J.C., Debry C., Goffaux M., Pineau J., Calomme G., Dubuc E., et al. Coagulation function in fresh frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 48 (2008) 108-117
29. Schlenke P., Hervig T., Hervé I., Wiesel M.L., Kientz D., Pinkoski L., et al. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 48 (2008) 697-705